Motoi T, Uchiyama T, Uchino H, Ueda R, Araki K
First Division of Internal Medicine, Faculty of Medicine, Kyoto University.
Jpn J Cancer Res. 1988 May;79(5):593-9. doi: 10.1111/j.1349-7006.1988.tb00028.x.
Using an enzyme-linked immunosorbent assay (ELISA) technique, we measured the soluble interleukin 2 receptor (s-IL-2R) levels in the sera of patients with adult T-cell leukemia (ATL) in Japan. The s-IL-2R levels in the sera of the ATL patients were markedly higher (range 540-310, 400 U/ml, mean +/- SD = 62,800 +/- 81,000 U/ml, n = 42) than those in normal individuals (range 42-950 U/ml, mean +/- SD = 322 +/- 198 U/ml, n = 35, P less than 0.01). The patients with acute-type or lymphoma-type ATL had high s-IL-2R levels (range 11,900-310,400 U/ml, mean +/- SD = 110,340 +/- 370 U/ml, n = 15; range 26,400-214,400 U/ml, mean +/- SD = 90,170 +/- 59,040 U/ml, n = 7, respectively). All of the patients with hypercalcemia (Ca greater than 10 mg/dl) or elevated serum LDH levels (LDH greater than 500 IU/liter) also had s-IL-2R levels above 10,000 U/ml. The high s-IL-2R levels in the sera of ATL patients indicate abnormal IL-2 receptor production and its release from the leukemic cells in vivo. Thus, the serum s-IL-2R level may be a sensitive and useful marker to monitor the total amount of tumor cells in ATL, especially in the lymphoma type. We next examined the serum s-IL-2R levels in human T-cell leukemia/lymphoma virus type-I (HTLV-I) seropositive healthy carriers to investigate whether there might be abnormal IL-2 receptor expression in such individuals. However, there was no statistically significant difference between the s-IL-2R level of 71 HTLV-I seropositive healthy carriers (range 65-880 U/ml, mean +/- SD = 394 +/- 212 U/ml) and that of 71 age- and sex-matched normal individuals (range 33-950 U/ml, mean +/- SD = 357 +/- 224 U/ml) who lived in Okinawa Prefecture.
我们采用酶联免疫吸附测定（ELISA）技术，检测了日本成人T细胞白血病（ATL）患者血清中可溶性白细胞介素2受体（s-IL-2R）的水平。ATL患者血清中的s-IL-2R水平显著高于正常个体（ATL患者范围为540 - 310400 U/ml，平均±标准差 = 62800±81000 U/ml，n = 42；正常个体范围为42 - 950 U/ml，平均±标准差 = 322±198 U/ml，n = 35，P < 0.01）。急性型或淋巴瘤型ATL患者的s-IL-2R水平较高（急性型范围为11900 - 310400 U/ml，平均±标准差 = 110340±370 U/ml，n = 15；淋巴瘤型范围为26400 - 214400 U/ml，平均±标准差 = 90170±59040 U/ml，n = 7）。所有高钙血症（血钙>10 mg/dl）或血清乳酸脱氢酶水平升高（LDH>500 IU/升）的患者，其s-IL-2R水平也高于10000 U/ml。ATL患者血清中高s-IL-2R水平表明体内白血病细胞产生并释放了异常的IL-2受体。因此，血清s-IL-2R水平可能是监测ATL中肿瘤细胞总量的一个敏感且有用的标志物，尤其是在淋巴瘤型中。接下来，我们检测了人类T细胞白血病/淋巴瘤病毒I型（HTLV-I）血清阳性健康携带者血清中的s-IL-2R水平，以研究此类个体中是否存在异常的IL-2受体表达。然而，71名HTLV-I血清阳性健康携带者的s-IL-2R水平（范围为65 - 880 U/ml，平均±标准差 = 394±212 U/ml）与居住在冲绳县的71名年龄和性别匹配的正常个体（范围为33 - 950 U/ml，平均±标准差 = 357±224 U/ml）相比，差异无统计学意义。
